Praxis Precision Medicines, Inc. (PRAX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$252.96-2.30%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Praxis Precision Medicines, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	630,486
EPS	—	-4.042
Annual ending 2026-12-31
Revenue	—	925,484
EPS	—	-13.714
Annual ending 2027-12-31
Revenue	—	346.36M
EPS	—	-10.034

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway into 2028	A primary condition in Praxis Precision Medicines, Inc.'s published investment case. The stated target is >= $1.4 billion.	Intact	cash falls below $1 billion before 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Cash and investments remained steady at approximately $1.4 billion from March 31, 2026 to June 30, 2026, supporting management's claim of runway into 2028. The trajectory is delivering as cash levels have been maintained following a significant capital raise. Delivery assessment Oct 24, 2026
Improve operating income	A primary condition in Praxis Precision Medicines, Inc.'s published investment case. The stated target is operating loss improves from -$105.86M in 2026-Q1.	Intact	operating loss worsens beyond -$110 million next year	Operating income: $-96.904M FY2026-Q2; GAAP. Published target: operating loss improves from -$105.86M in 2026-Q1. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-96,904,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e9555342-5541-4c27-9883-5af861b8f1d7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating expenses increased with R&D and G&A investments supporting pipeline and commercial activities, resulting in a net loss increase from $71.1 million in 2025-Q2 to $83.7 million in 2026-Q2. The trajectory shows increased spending consistent with stated priorities but no improvement in operating income yet. Delivery assessment Oct 24, 2026
FDA approval progress for relutrigine	A supporting condition in Praxis Precision Medicines, Inc.'s published investment case. The stated target is NDA review completed without further delay.	Under Pressure	FDA delays approval beyond 2026-Q4	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue potential of over $20 billion	Praxis aims for over $20 billion in revenue from key drugs.	Improving	revenue falls below $15 billion in FY26	Revenue: $0 FY2026-Q2; GAAP. Published target: >= $20 billion. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-10.03

$-9.66 → $-10.03 · observed estimates

FY2027 revenue$0.35B

$0.34B → $0.35B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-9.66	$342,357,440	15 / 18
2026-07-25	$-9.66	$342,357,440	15 / 18
2026-07-26	$-9.66	$342,357,440	15 / 18
2026-07-27	$-9.66	$342,357,440	15 / 18
2026-07-28	$-9.66	$342,357,440	15 / 18
2026-07-29	$-9.66	$342,357,440	15 / 18
2026-07-30	$-10.40	$342,339,589	13 / 14
2026-07-31	$-10.40	$342,339,756	13 / 14
2026-08-01	$-10.40	$342,339,756	13 / 14
2026-08-02	$-10.40	$342,339,756	13 / 14
2026-08-03	$-10.40	$342,339,756	13 / 14
2026-08-04	$-10.40	$342,339,756	13 / 14
2026-08-05	$-10.40	$342,339,756	13 / 14
2026-08-06	$-10.40	$342,339,756	13 / 14
2026-08-07	$-10.40	$342,339,756	13 / 14
2026-08-08	$-9.45	$342,806,690	15 / 18
2026-08-09	$-10.40	$342,339,756	13 / 14
2026-08-10	$-9.45	$342,806,690	15 / 18
2026-08-12	$-9.80	$343,497,740	15 / 18
2026-08-13	$-10.40	$342,339,756	13 / 14
2026-08-14	$-10.40	$342,339,756	13 / 14
2026-08-15	$-10.40	$342,339,756	13 / 14
2026-08-16	$-10.40	$342,339,756	13 / 14
2026-08-17	$-10.40	$342,339,756	13 / 14
2026-08-18	$-10.40	$342,339,756	13 / 14
2026-08-19	$-10.40	$342,339,756	13 / 14
2026-08-20	$-10.03	$345,282,139	13 / 14
2026-08-21	$-9.91	$349,608,492	13 / 14
2026-08-22	$-9.91	$349,608,492	13 / 14
2026-08-23	$-9.91	$349,608,492	13 / 14
2026-08-24	$-9.91	$349,608,492	13 / 14
2026-08-25	$-9.91	$349,608,492	13 / 14
2026-08-26	$-9.91	$349,608,492	13 / 14
2026-08-27	$-9.91	$349,608,492	13 / 14
2026-08-28	$-9.91	$349,608,492	13 / 14
2026-08-29	$-9.91	$349,608,492	13 / 14
2026-08-30	$-9.91	$349,608,492	13 / 14
2026-08-31	$-9.91	$349,608,492	13 / 14
2026-09-01	$-9.91	$349,608,492	13 / 14
2026-09-02	$-9.91	$349,608,492	13 / 14
2026-09-03	$-9.91	$349,608,492	13 / 14
2026-09-04	$-9.91	$349,608,492	13 / 14
2026-09-05	$-9.91	$349,608,492	13 / 14
2026-09-06	$-9.91	$349,608,492	13 / 14
2026-09-07	$-9.91	$349,608,492	13 / 14
2026-09-08	$-9.91	$349,608,492	13 / 14
2026-09-09	$-9.91	$349,608,492	13 / 14
2026-09-10	$-9.91	$349,608,492	13 / 14
2026-09-11	$-9.91	$349,608,492	13 / 14
2026-09-12	$-9.91	$349,608,492	13 / 14
2026-09-13	$-9.91	$349,608,492	13 / 14
2026-09-14	$-9.91	$349,608,492	13 / 14
2026-09-15	$-9.91	$349,608,492	13 / 14
2026-09-16	$-9.91	$349,608,492	13 / 14
2026-09-17	$-9.91	$349,608,492	13 / 14
2026-09-18	$-9.91	$349,608,492	13 / 14
2026-09-19	$-9.91	$349,608,492	13 / 14
2026-09-20	$-9.91	$349,608,492	13 / 14
2026-09-21	$-9.91	$349,608,492	13 / 14
2026-09-22	$-9.91	$349,608,492	13 / 14
2026-09-23	$-9.91	$349,608,492	13 / 14
2026-09-24	$-9.91	$349,608,492	13 / 14
2026-09-25	$-9.91	$349,608,492	13 / 14
2026-09-26	$-9.91	$349,608,139	13 / 14
2026-09-27	$-9.91	$349,608,139	13 / 14
2026-09-28	$-9.91	$349,608,139	13 / 14
2026-09-29	$-9.91	$349,608,139	13 / 14
2026-09-30	$-9.91	$349,608,139	13 / 14
2026-10-01	$-9.91	$349,608,139	13 / 14
2026-10-02	$-9.95	$347,998,551	13 / 14
2026-10-03	$-9.95	$347,998,551	13 / 14
2026-10-04	$-9.95	$347,999,433	13 / 14
2026-10-05	$-9.95	$347,999,433	13 / 14
2026-10-06	$-9.95	$347,999,433	13 / 14
2026-10-07	$-9.94	$348,377,669	13 / 14
2026-10-08	$-9.94	$348,377,669	13 / 14
2026-10-09	$-9.94	$348,377,669	13 / 14
2026-10-10	$-9.94	$348,377,669	13 / 14
2026-10-11	$-9.94	$348,377,669	13 / 14
2026-10-12	$-9.94	$348,377,669	13 / 14
2026-10-13	$-9.94	$348,377,669	13 / 14
2026-10-14	$-9.94	$348,377,669	13 / 14
2026-10-15	$-9.94	$348,377,669	13 / 14
2026-10-16	$-9.74	$354,458,187	14 / 14
2026-10-17	$-9.74	$354,458,187	14 / 14
2026-10-18	$-10.03	$346,358,022	15 / 15
2026-10-19	$-10.03	$346,358,022	15 / 15
2026-10-20	$-10.03	$346,358,022	15 / 15
2026-10-21	$-10.03	$346,358,022	15 / 15
2026-10-22	$-10.03	$346,358,022	15 / 15
2026-10-23	$-10.03	$346,358,022	15 / 15
2026-10-24	$-10.03	$346,358,022	15 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	15	1	1
2026-06-01	16	1	1
2026-07-01	17	1	1
2026-08-01	17	1	1
2026-09-01	17	1	1
2026-10-01	19	1	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 19 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 14

$706.00New observation · no comparable prior

$0$388.30$776.60

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway into 2028Direct metric needs a verified mapping
Improve operating incomeOperating income: $-96.904M
FDA approval progress for relutriginePublished status: Under Pressure
Achieve revenue potential of over $20 billionRevenue: $0

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-38.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Praxis Precision Medicines, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative growth, with the long-term thesis tied to advancing pipeline programs and preparing launches for ulixacaltamide and relutrigine. The thesis is in watch status: the signal recently improved from mixed to mildly favorable, but recent financial performance remains well below its industry cohort.

What's priced into Praxis Precision Medicines, Inc.

PRAX trades at a 64.36% premium to peers, while valuation-model confidence is low and the valuation case depends on future optionality, meaning potential value from launches and pipeline programs. The evidence does not specify exactly what investors assume, but the premium suggests meaningful expectations for those programs despite the company being loss-making.

What the fundamentals likely do

Near term, management says cash and investments of about $1.4 billion support runway into 2028, and it reports progress on launch readiness and clinical and regulatory milestones. Recent results were weak relative to the industry cohort, although an August earnings beat and a strategic partnership were positive developments; a guidance cut remains a key risk. The sector backdrop is supportive, but weakening job growth could increase recession concerns across cyclical and healthcare names.

What Praxis Precision Medicines, Inc. hinges on

The multi-year thesis hinges on whether PRAX advances its pipeline and is ready to launch ulixacaltamide and relutrigine ahead of their early-2027 FDA decision dates. In the near term, guidance, job-market trends, and earnings and guidance from healthcare bellwethers could shift the backdrop. Cash staying near recent levels and continued clinical progress would support management's stated priorities, while weaker execution or guidance would challenge them.